Last data update: May 20, 2024. (Total: 46824 publications since 2009)
Records 1-2 (of 2 Records) |
Query Trace: Bosserman EA[original query] |
---|
A literature review of laboratory-acquired brucellosis
Traxler RM , Lehman MW , Bosserman EA , Guerra MA , Smith TL . J Clin Microbiol 2013 51 (9) 3055-62 Brucellosis is a bacterial zoonotic disease which has been associated with laboratory-acquired infections. No recent reviews have addressed the characteristics of laboratory-acquired brucellosis (LAB). English-language literature was reviewed to identify reports of laboratory exposures to Brucella spp. and LAB cases between 1982 and 2007. Evaluation of twenty-eight case reports identified 167 potentially exposed laboratory workers of which 71 had LAB. Nine reports were identified that summarized an additional 186 cases of LAB. Only 18 (11%) exposures were due to laboratory accidents, 147 (88%) exposures were due to aerosolization of organisms during routine identification activities and 2 (1%) exposures were unknown. Brucella melitensis was the causative agent for 80% (135/167) of the exposures. Workers with high risk exposures were 9.3 times more likely to develop LAB than workers with low risk exposures (95% CI, 3.0-38.6; P<0.0001); they were also 0.009 times as likely to develop LAB if they took antimicrobial PEP than those who did not take PEP (95% CI, 0-0.042; P<0.0001). Median incubation period in case and summary reports was eight weeks (range 1-40 weeks). Antimicrobial PEP is effective in preventing LAB. The incubation period may be used to identify appropriate serological and symptom surveillance timeframes for exposed laboratory workers. |
Utility of antimicrobial susceptibility testing in Trichomonas vaginalis-infected women with clinical treatment failure
Bosserman EA , Helms DJ , Mosure DJ , Secor WE , Workowski KA . Sex Transm Dis 2011 38 (10) 983-7 BACKGROUND: Antimicrobial resistance is one of the causes of treatment failure in women after standard nitroimidazole therapy for Trichomonas vaginalis infections. The Centers for Disease Control and Prevention provides drug susceptibility testing and guidance for treatment failures but the efficacy of the alternate recommendations has not been assessed. METHODS: T. vaginalis isolates from women who had failed at least 2 courses of standard therapy for trichomoniasis were submitted to the Centers for Disease Control and Prevention for susceptibility testing. Alternative treatment recommendations were provided based on in vitro drug susceptibility results and clinical outcomes were collected. RESULTS: Drug susceptibility results were available for 175 women tested between January 2002 and January 2008. In vitro, 115 of the 175 isolates demonstrated metronidazole resistance. For all isolates resistant to metronidazole, in vitro resistance to tinidazole was similar or lower. Clinical treatment outcomes were available for 72 women. Of the women receiving an alternative recommended nitroimidazole regimen, 30 (83%) of 36 were cured compared with 8 (57%) of 14 women who received a lower dose than recommended. Clinical and microbiologic success was attained in 59 (82%) of 72 women whose follow-up information was available, with some women requiring multiple treatment courses. CONCLUSIONS: Clinical and microbiologic cure rates were higher for women who were treated in accordance with the recommendation provided after in vitro testing compared with those who received a lower dose or a different drug. Susceptibility testing leading to tailored treatment may have a beneficial role for management of women with persistent trichomoniasis. |
- Page last reviewed:Feb 1, 2024
- Page last updated:May 20, 2024
- Content source:
- Powered by CDC PHGKB Infrastructure